Cell Signaling Technology

Product Pathways - Wnt / Hedgehog / Notch

Wnt5a/b (C27E8) Rabbit mAb #2530

Applications Reactivity MW (kDa) Source Isotype
W H M 45 Rabbit IgG

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse
Species enclosed in parentheses are predicted to react based on 100% sequence homology. Species cross-reactivity is determined by Western blot.

Specificity / Sensitivity

Wnt5a/b (C27E8) Rabbit mAb detects endogenous levels of Wnt5a and Wnt5b proteins. This antibody cross-reacts with an unidentified protein between 55 and 60 kDa.

Source / Purification

Monoclonal antibodies were generated by immunizing rabbits with a synthetic peptide (Blue Carriar-coupled) corresponding to residues surrounding Glu176 of human Wnt5a protein.

Western Blotting

Western Blotting

Western blot analysis of total cell lysates from HeLa, LN18, PANC1 cells and HeLa cells conditioned medium (CM) using Wnt5a/b (C27E8) Rabbit mAb.

Background

The Wnt family includes several secreted glycoproteins that play important roles in animal development (1). There are 19 Wnt genes in the human genome that encode functionally distinct Wnt proteins (2). Wnt members bind to the Frizzled family of seven-pass transmembrane proteins and activate several signaling pathways (3). The canonical Wnt/β-catenin pathway also requires a coreceptor from the low-density lipoprotein receptor family (4). Aberrant activation of Wnt signaling pathways is involved in several types of cancers (5).

Wnt-5a has been shown to signal through the canonical Wnt pathways as well as through non-canonical pathways and is up-regulated in various types of human cancers (6-8). In melanoma, Wnt5a is thought to directly affect cell motility and metastasis (9).

  1. Cadigan, K.M. and Nusse, R. (1997) Genes Dev. 11, 3286-3305.
  2. Moon, R.T. et al. (1997) Trends Genet. 13, 157-162.
  3. Kohn, A.D. and Moon, R.T. (2004) Cell Calcium 38, 439-446.
  4. Logan, C.Y. and Nusse, R. (2004) Annu. Rev. Cell Dev. Biol. 20, 781-810.
  5. Giles, R.H. et al. (2003) Biochim. Biophys. Acta. 1653, 1-24.
  6. Mikels, A.J. and Nusse, R. (2006) PLoS Biol. 4, e115.
  7. Katoh, M. and Katoh, M. (2007) Int. J. Mol. Med. 19, 273-278.
  8. Katoh, M. (2005) Oncol. Rep. 14, 1583-1588.
  9. Weeraratna, A.T. et al. (2002) Cancer Cell 1, 279-288.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes